Where does Cadent Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cadent Therapeutics, Inc. ranks #16,662 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cadent Therapeutics, Inc. hold?

Cadent Therapeutics, Inc. holds 17 US utility patents granted between 2018 and 2023, spanning 4 technology areas.

What is Cadent Therapeutics, Inc.'s Innovation Score?

Cadent Therapeutics, Inc. has an Innovation Score of 28.1 out of 100 (26th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cadent Therapeutics, Inc. focus on?

Cadent Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 17 patents, ranking #1,155 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Cadent Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Cadent Therapeutics, Inc.'s recent grant velocity is +140% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cadent Therapeutics, Inc.'s patents?

Cadent Therapeutics, Inc.'s patents average 14.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cadent Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cadent Therapeutics, Inc.

USPTO PatentsView assignee record - 17 granted patents across 4 technology areas, recorded in grant years 2018–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cadent ranks #16,662 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 4 technology areas.

#16,662
of 49,997 US assignees by volume: 26th percentile
by Innovation Score (28.1/100): 14.3
avg claims per patent: +140%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16662 · US Corporation #16,662 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 17 grants
MID-PACK #16,662/49,997
PHOTO-FINISH Cabeau
CPC-NARROW A61P · 4 areas
INNOV-THIN 28.1/100
CLAIMS-RICH 14.3 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +140% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cabeau, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cadent’s 28.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (36%) Velocity 2.4 pts (9%) Breadth 7.1 pts (25%) Claim depth 8.6 pts (31%)

Qualcomm Incorporated · highest

85
Cadent Therapeutics · this assignee

28
3D Lighting… · lowest

7

What this shows Cadent's Innovation Score is 28.1/100 (26th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cadent?

Each dot is one of Cadent’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cadent’s own 14.3 claims/patent is at or below the 17.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cadent vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cadent's grants concentrate

Cadent Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (6 grants) versus a trough of 2 in 2018. By volume, Cadent sits between Ctxt PTY Ltd and Centre Hospitalier Regional Universitaire de Montpellier.

Cadent's three-year grant acceleration

Cadent Therapeutics, Inc. shows 4 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ctxt PTY

17
Cufer Asset L L C

17
Cutting Edge Prod…

17
Cabeau

17
Carver Scientific

17
Catalyst Bioscien…

17
Cellular Dynamics…

17
Centre Hospitalie…

17
Cadent Therapeuti… ◀

17

What this shows Cadent holds 17 patents at rank #16,687, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cadent

By rank, the assignees closest to #16,687 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Cadent's primary technology class.

Cadent's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 26th percentile higher than 26% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Cadent Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	2	11.8%
2019	3	17.6%
2020	6	35.3%
2021	2	11.8%
2022	2	11.8%
2023	2	11.8%

Which technologies does Cadent Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

C07D - Heterocyclic Compounds 17

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cadent Therapeutics, Inc.'s patent record in context - here's where to go next.

Cadent Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #16,662 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cadent Therapeutics, Inc. against Ctxt PTY Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.